

Rydym yn croesawu gohebiaeth yn y Gymraeg ac yn y Saesneg. We welcome correspondence in Welsh or English.

Dyddiad/Date: 6<sup>th</sup> October 2020  
Ein Cyf / Our Ref: 20-H-002

☎ 01639 648363  
✉ FOIA.Requests@wales.nhs.uk

[REDACTED]  
[REDACTED]

Corporate Services  
Headquarters  
1 Talbot Gateway  
Baglan  
Port Talbot, SA12 7BR

Dear [REDACTED],

I refer to your Freedom of Information Act Request acknowledged by ourselves on 4<sup>th</sup> August 2020. Your request sought information relating to Atopic Dermatitis.

**1. How many patients were treated within your Health Board with the following drugs within the specified time periods?**

Please note that this data is only available for August 2017 onwards.

Drug	01 August 2017 to 31 July 2018	01 August 2018 to 31 January 2020
Apremilast	83	140
Adalimumab	577	774
Dupilumab	0	42
Etanercept	673	672
Infliximab	240	279
Secukinumab	89	129
Ustekinumab	123	136



**2. How many patients were treated within your Health Board for atopic dermatitis within the specified time periods?**

Please note that we have included the number of patients admitted who are diagnosed with Atopic Dermatitis and patients who have attended the UV photo therapy clinics in Neath Port Talbot and Singleton Hospitals.

A patient could be admitted or treated several times within this period, so the number or treatments/admissions would be higher than the number of patients.

Attendance/treatment type	01 February 2017 to 31 July 2018	01 August 2018 to 31 January 2020
No of patients admitted	15	11
No of patients who received UV therapy	453	376

**3. How many patients were treated within your Health Board with the following drugs for atopic dermatitis within the specified time periods?**

Please note that we are not able to provide this information specific to patients with a diagnosis of Atopic Dermatitis. To obtain this information would involve a manual trawl and search of patient notes which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time. Therefore, we have provided figures for Dermatology as a whole.

Please further note that this data is only available for August 2017 onwards.

Drug	01 August 2017 to 31 July 2018	01 August 2018 to 31 January 2020
Apremilast	60	86
Adalimumab	85	117
Dupilumab	0	42
Etanercept	30	26
Infliximab	15	17
Secukinumab	45	39
Ustekinumab	100	92



**4. Please specify how patients treated with the following drugs are coded (OPCS code) within your Health Board:**

Drug	OPCS code
Apremilast	X92.1
Adalimumab	X92.1
Dupilumab	Not on our OPCS drugs list
Etanercept	X92.1
Infliximab	X92.1
Secukinumab	X92.1
Ustekinumab	X89.1

**5. Please provide the number of patients treated in the homecare setting for atopic dermatitis within the specified time periods:**

Please note that we are not able to provide this information specific to patients with a diagnosis of Atopic Dermatitis. To obtain this information would involve a manual trawl and search of patient notes which we have estimated would significantly exceed the 18 hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

Number of patients treated in the homecare setting for atopic dermatitis between 01 February 2017 and 31 July 2018	Number of patients treated in the homecare setting for atopic dermatitis between 01 August 2018 and 31 January 2020

**6. How many of your Health Board’s homecare patients were treated with the following drugs for atopic dermatitis within the specified time periods?**

Please note that we are not able to provide this information specific to patients with a diagnosis of Atopic Dermatitis. To obtain this information would involve a manual trawl and search of patient notes which we have estimated would significantly exceed the 18



hours limit set down by the FOI Act as the reasonable limit. Section 12 of the FOI Act provides that we are not obliged to spend in excess of 18 hours in any sixty day period locating, retrieving and identifying information in order to deal with a request for information and therefore we are withholding this information at this time.

Therefore, we have provided figures for Dermatology as a whole.

Please further note that this data is only available for August 2017 onwards.

Drug	01 August 2017 to 31 July 2018	01 August 2018 to 31 January 2020
Apremilast	0	0
Adalimumab	85	117
Dupilumab	0	41
Etanercept	30	26
Infliximab	0	0
Secukinumab	45	39
Ustekinumab	100	92

I hope this information is helpful. If you require anything further please contact us at [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request please contact me directly at the address below or register your complaint via [FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk).

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2<sup>nd</sup> Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 029 2067 8400.

Yours sincerely



Pam Wenger  
**Director of Corporate Governance**

